Direct acting antiviral (DAA) therapy has transformed the management of human Immunodeficiency virus (HIV) and hepatitis C (HCV) coinfected patients with advanced liver disease. STOP-Coinfection was a multi-center, prospective and retrospective, open-label study using sofosbuvir-based DAA therapy to treat HIV/HCV coinfected participants pre- or post-liver transplant (LT).
The study included adults living with HIV and chronic HCV and end-stage liver disease pre-LT and any stage of liver disease post-LT; HCV genotypes 1, 4, 5 or 6 with pre-treatment serum HCV RNA ?1000 IU/mL. Pre-LT participants had a baseline Child’s Pugh Turcotte (CPT) score ? 7 and Model for End-Stage Liver Disease (MELD) ? 6 to ? 30. Endpoints were proportion of participants achieving sustained virologic response (SVR) and reversal in decompensation.
68 participants with end stage liver disease were enrolled, 26 had hepatocellular carcinoma. 42 participants were treated pre-LT and 26 post-LT. 93% achieved SVR and DAA therapy was well tolerated. All participants completed therapy without dose reduction or transfusion; 8 required ?2 courses of therapy. All participants had controlled HIV on ART with stable CD4 counts and occasional low detectable HIV viral load. 28 participants experienced 41 serious adverse events during treatment. Despite HCV cure, 12 end-stage liver disease participants required subsequent LT, 7 for decompensated liver disease. In 33 of the 42 participants treated pre-LT, MELD was available pre and post DAA treatment and pre-LT. Among the 19 participants with pretreatment MELD<15, 53% had improvement in MELD (-1 to -6); 37% had worsening of MELD (2-15); 10% no change; and 26% had post DAA treatment MELD ?15. Among those 14 participants with pretreatment MELD ?15, 64% had improvement in MELD (-1 to -30); 29% had worsening of MELD (2 to 21); 7% no change; and 43% had MELD <15. 13 participants died, 10 with decompensated liver disease pre-LT and 3 post-LT. Overall, transplant free survival was 42.8% at 4 years (figure A) and post-LT survival was 87.9% at 5 years (figure B).
We conclude that sofosbuvir-based DAA therapy is safe and highly effective in HCV-HIV patients with decompensated liver disease and post-LT, with post-LT survival rates comparable to other indications. This removes one of the last barriers to LT in this challenging cohort of recipients and likely will increase LT-free survival.
![]()